Genital Herpes – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Genital Herpes – Pipeline Review, H2 2017’, provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Genital Herpes

The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects

The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Genital Herpes

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Admedus Ltd

AiCuris GmbH & Co KG

Biomere LLC

Foamix Pharmaceuticals Ltd

Genocea Biosciences Inc

GenVec Inc

Immune Design Corp

JN-International Medical Corp

NanoBio Corp

NanoViricides Inc

Profectus BioSciences Inc

Redbiotec AG

Sanofi Pasteur SA

Starpharma Holdings Ltd

Vaccibody AS

Vical Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Genital Herpes - Overview 6

Genital Herpes - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Genital Herpes - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Genital Herpes - Companies Involved in Therapeutics Development 23

Abivax SA 23

Admedus Ltd 23

AiCuris GmbH & Co KG 24

Biomere LLC 24

Foamix Pharmaceuticals Ltd 25

Genocea Biosciences Inc 25

GenVec Inc 26

Immune Design Corp 26

JN-International Medical Corp 27

NanoBio Corp 27

NanoViricides Inc 28

Profectus BioSciences Inc 28

Redbiotec AG 29

Sanofi Pasteur SA 29

Starpharma Holdings Ltd 30

Vaccibody AS 30

Vical Inc 31

Genital Herpes - Drug Profiles 32

ABX-196 - Drug Profile 32

acyclovir - Drug Profile 33

Aspidasept - Drug Profile 34

astodrimer - Drug Profile 35

G-103 - Drug Profile 40

GEN-003 - Drug Profile 41

genital herpes (virus like particle) vaccine - Drug Profile 47

genital herpes vaccine - Drug Profile 48

genital herpes vaccine - Drug Profile 51

genital herpes vaccine - Drug Profile 52

genital herpes vaccine - Drug Profile 53

genital herpes vaccine - Drug Profile 54

GV-2207 - Drug Profile 55

herpes simplex virus [type 1, 2] vaccine - Drug Profile 56

herpes simplex virus 2 vaccine - Drug Profile 57

herpes simplex virus 2 vaccine - Drug Profile 58

herpes simplex virus 2 vaccine - Drug Profile 59

herpes simplex virus 2 vaccine - Drug Profile 61

herpes simplex virus 2 vaccine - Drug Profile 62

HSV-529 - Drug Profile 63

NN-001 - Drug Profile 65

pritelivir - Drug Profile 66

Profavax HSV-1 - Drug Profile 69

Profavax HSV-2 - Drug Profile 70

Small Molecule for Genital Herpes - Drug Profile 71

Theravax HSV-1 - Drug Profile 72

Theravax HSV-2 - Drug Profile 73

VCLHB-01 - Drug Profile 74

VCLHM-01 - Drug Profile 76

VMTX-004 - Drug Profile 78

Genital Herpes - Dormant Projects 79

Genital Herpes - Discontinued Products 81

Genital Herpes - Product Development Milestones 82

Featured News & Press Releases 82

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

List of Tables

List of Tables

Number of Products under Development for Genital Herpes, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Genital Herpes – Pipeline by Abivax SA, H2 2017

Genital Herpes – Pipeline by Admedus Ltd, H2 2017

Genital Herpes – Pipeline by AiCuris GmbH & Co KG, H2 2017

Genital Herpes – Pipeline by Biomere LLC, H2 2017

Genital Herpes – Pipeline by Foamix Pharmaceuticals Ltd, H2 2017

Genital Herpes – Pipeline by Genocea Biosciences Inc, H2 2017

Genital Herpes – Pipeline by GenVec Inc, H2 2017

Genital Herpes – Pipeline by Immune Design Corp, H2 2017

Genital Herpes – Pipeline by JN-International Medical Corp, H2 2017

Genital Herpes – Pipeline by NanoBio Corp, H2 2017

Genital Herpes – Pipeline by NanoViricides Inc, H2 2017

Genital Herpes – Pipeline by Profectus BioSciences Inc, H2 2017

Genital Herpes – Pipeline by Redbiotec AG, H2 2017

Genital Herpes – Pipeline by Sanofi Pasteur SA, H2 2017

Genital Herpes – Pipeline by Starpharma Holdings Ltd, H2 2017

Genital Herpes – Pipeline by Vaccibody AS, H2 2017

Genital Herpes – Pipeline by Vical Inc, H2 2017

Genital Herpes – Dormant Projects, H2 2017

Genital Herpes – Dormant Projects, H2 2017 (Contd..1), H2 2017

Genital Herpes – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Genital Herpes, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports